Volume 33, Issue 1 (11-2023)
J Mazandaran Univ Med Sci 2023, 33(1): 86-96 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Makhlough A, Mirzaei Ilali N, Darvishnia D, Darvishi-Khezri H, Sharifipour A, Mehravaran H, et al . Severe Acute Kidney Injury and Chronic Kidney Disease are Paramount Risk Factors for Mortality in Hospitalized Cases with COVID-19. J Mazandaran Univ Med Sci 2023; 33 (1) :86-96
URL: http://jmums.mazums.ac.ir/article-1-19806-en.html
URL: http://jmums.mazums.ac.ir/article-1-19806-en.html
Atieh Makhlough 
, Narges Mirzaei Ilali , David Darvishnia , Hadi Darvishi-Khezri , Ali Sharifipour , Hossein Mehravaran , Masoud Aliyali , Sepideh Safanavaiee , Siavash Abedi , Babak Eslami
, Narges Mirzaei Ilali , David Darvishnia , Hadi Darvishi-Khezri , Ali Sharifipour , Hossein Mehravaran , Masoud Aliyali , Sepideh Safanavaiee , Siavash Abedi , Babak Eslami
Abstract: (406 Views)
Background and purpose: Novel coronavirus (COVID-19) can cause acute kidney injury (AKI), and underlying kidney diseases worsen the prognosis of COVID-19 patients.
Materials and methods: This observational study examined the clinical and laboratory outcomes of patients with COVID-19 and assessed the major risk factors for death and intensive care unit (ICU) hospitalization in COVID-19 patients. The sample consisted of 296 COVID-19 patients with or without underlying kidney diseases. In total, 37 patients died (mean age: 66.6 ± 17.6).
Results: Most patients who passed away initially suffered from shortness of breath (37.8%), cough (21.6%), old age, insulin use, central nervous system (CNS) disease, septic shock, hypoalbuminemia (P<0.0001), and high international normalized ratio (P<0.0001). Median time to death was higher in patients hospitalized in the ICU than in those without chronic kidney disease (OR=3.08; P=0.006). The use of azithromycin and ceftriaxone was lower than the use of Recigen and meropenem in deceased people (P<0.0001).
Conclusion: The risk of mortality and ICU hospitalization was higher in patients with CKD than in those without CKD. The results revealed the therapeutic effects of azithromycin and ceftriaxone and the side effects of Recigen and meropenem in deceased COVID-19 patients. In addition, low albumin level, high INR, neutrophil count, white blood cell (WBC) significantly increased the risk of death in these patients.
Materials and methods: This observational study examined the clinical and laboratory outcomes of patients with COVID-19 and assessed the major risk factors for death and intensive care unit (ICU) hospitalization in COVID-19 patients. The sample consisted of 296 COVID-19 patients with or without underlying kidney diseases. In total, 37 patients died (mean age: 66.6 ± 17.6).
Results: Most patients who passed away initially suffered from shortness of breath (37.8%), cough (21.6%), old age, insulin use, central nervous system (CNS) disease, septic shock, hypoalbuminemia (P<0.0001), and high international normalized ratio (P<0.0001). Median time to death was higher in patients hospitalized in the ICU than in those without chronic kidney disease (OR=3.08; P=0.006). The use of azithromycin and ceftriaxone was lower than the use of Recigen and meropenem in deceased people (P<0.0001).
Conclusion: The risk of mortality and ICU hospitalization was higher in patients with CKD than in those without CKD. The results revealed the therapeutic effects of azithromycin and ceftriaxone and the side effects of Recigen and meropenem in deceased COVID-19 patients. In addition, low albumin level, high INR, neutrophil count, white blood cell (WBC) significantly increased the risk of death in these patients.
Type of Study: Research(Original) |
Subject:
Nephrology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
